Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies

The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 a...

Full description

Bibliographic Details
Main Authors: Rebecca Adams, Gabriel Osborn, Bipashna Mukhia, Roman Laddach, Zena Willsmore, Alicia Chenoweth, Jenny L C Geh, Alastair D MacKenzie Ross, Ciaran Healy, Linda Barber, Sophia Tsoka, Victoria Sanz-Moreno, Katie E Lacy, Sophia N Karagiannis
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
melanoma
macrophages
monoclonal antibodies
immunotherapy
checkpoint inhibitors
polarization
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127284

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127284

Similar Items